BioCryst Pharmaceuticals, Inc. (BCRX) vs Viridian Therapeutics, Inc. (VRDN)
A side-by-side comparison of BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCRX
BioCryst Pharmaceuticals, Inc.
$7.95HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
VRDN
Viridian Therapeutics, Inc.
$18.22HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — BCRX vs VRDN
growth of $100 · dividends reinvested · last 10yBCRX +78.8% (+6.0%/yr)VRDN -83.3% (-16.4%/yr)BCRX compounded faster over this window
Log scale — wide-divergence pair
BCRX VRDN
BCRX vs VRDN: by the numbers
- •VRDN is the larger company ($2.06B vs $2.02B market cap).
- •Both run net losses; BCRX's is the smaller (-40.90% vs -544.06% net margin).
- •VRDN grew revenue faster over the past five years (93.92% vs 64.07% CAGR).
Metrics side by side
Valuation
| Metric | BCRX | VRDN |
|---|---|---|
| P/S ratio | 2.15 | 29.02 |
| P/B ratio | N/A | 3.66 |
| FCF yield | 17.67% | N/A |
Profitability
| Metric | BCRX | VRDN |
|---|---|---|
| Gross margin | 97.82% | 99.55% |
| Operating margin | 38.98% | -512.91% |
| Net margin | -40.90% | -544.06% |
| ROE | N/A | -58.45% |
| ROIC | -89.73% | -39.18% |
Growth (annualized)
| Metric | BCRX | VRDN |
|---|---|---|
| Revenue CAGR (5Y) | 64.07% | 93.92% |
| Total return CAGR (5Y) | -10.02% | 1.64% |
Frequently asked
- Which has grown faster, BCRX or VRDN?
- Over the past five years, VRDN grew revenue faster — BCRX at a 64.07% CAGR versus VRDN at 93.92%.
- How have BCRX and VRDN total returns compared?
- Over the past 10 years, BCRX delivered 5.82% and VRDN delivered -16.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
BioCryst Pharmaceuticals ROEViridian Therapeutics ROEBioCryst Pharmaceuticals operating marginViridian Therapeutics operating marginBioCryst Pharmaceuticals revenue growthViridian Therapeutics revenue growthBioCryst Pharmaceuticals free cash flowViridian Therapeutics free cash flow
BioCryst Pharmaceuticals & Viridian Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.